AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

PERINDOPRIL ERBUMINE

9 registrations across 3 African markets— 6 active

Markets with PERINDOPRIL ERBUMINE

Recent registrations

Brand / ProductMarketHolderStatusExpires
CIPLA PERINDOPRIL 8 mg🇿🇦South AfricaCipla Medpro (Pty) LtdsuspendedApr 2026
CIPLASYL 2🇿🇦South AfricaCipla Medpro (Pty) LtdsuspendedJul 2025
PANOPRIST 4MG COMPRIME BOITE DE 30🇨🇮Côte d'IvoireSANDOZ GMBHexpiredDec 2018
CIPLASYL 8🇿🇦South AfricaCipla Medpro (Pty) LtdactiveJan 1900
CIPLA PERINDOPRIL 4 mg🇿🇦South AfricaCipla Medpro (Pty) LtdactiveJan 1900
CIPLASYL 4🇿🇦South AfricaCipla Medpro (Pty) LtdactiveJan 1900
PANOPRIST
comprimé / 8 mg
🇸🇳SenegalSANDOZ GMBHactive
PANOPRIST
comprimé / 4 mg
🇸🇳SenegalSANDOZ GMBHactive
PANOPRIST
comprimé / 4 mg
🇸🇳SenegalSANDOZ GMBHactive

PERINDOPRIL ERBUMINE in Africa — Regulatory Overview

PERINDOPRIL ERBUMINE is registered across 3 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Senegal, Côte d'Ivoire. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 6 (67%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.